Profound Research LLC (Site 0444)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Lung cancer

Running trials

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

  NCT05609968· Phase 3· Merck Sharp & Dohme LLC· Source